Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
Completed · Phase 2
Conditions studied: Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
In brief
To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment
Key facts
- Study ID
- NCT01611558
- Run by
- Bristol-Myers Squibb
- People needed
- 40
- Starts
- 2012-08-21
- Expected to finish
- 2019-07-03
- Last updated by the study team
- 2020-07-13
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Yale University School Of Medicine — New Haven, Connecticut, United States
- AdventHealth Cancer Institute — Orlando, Florida, United States
- H. Lee Moffitt Cancer Center — Tampa, Florida, United States
- Winship Cancer Institute. — Atlanta, Georgia, United States
- Georgia Regents University — Augusta, Georgia, United States
- Dr. Sudarshan K. Sharma, Ltd. — Hinsdale, Illinois, United States
- Indiana University Health Melvin And Bren Simon Cancer Center — Indianapolis, Indiana, United States
- Women'S Cancer Care — Covington, Louisiana, United States
- Dana Farber Cancer Institute. — Boston, Massachusetts, United States
- Memorial Sloan Kettering Nassau — New York, New York, United States
- Montefiore Medical Center — The Bronx, New York, United States
- The Charlotte-Mecklenburg Hospital Authority — Charlotte, North Carolina, United States
- Duke University Medical Center — Durham, North Carolina, United States
- MetroHealth Medical Center — Cleveland, Ohio, United States
- Peggy and Charles Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- Oklahoma Cancer Specialists and Research Institute, LLC — Tulsa, Oklahoma, United States
- Magee-Womens Hospital Of Upmc — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.